{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    43,
    44,
    45,
    46,
    47,
    48,
    49,
    50,
    51,
    57,
    62,
    63,
    70
  ],
  "modelUsed": "gemini-2.5-pro",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_llm_1",
        "definition": "Administration of study treatment, which is defined as Time = 0 min",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Once bedside PG reaches <60 mg/dL, the insulin infusion is stopped and approximately 5 minutes later study drug is administered.  Indicates Time = 0 min."
      },
      {
        "id": "anchor_1",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Screening\nPeriod"
      },
      {
        "id": "anchor_2",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed Consent"
      },
      {
        "id": "anchor_3",
        "definition": "Procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_interval_5",
        "type": "Interval",
        "interval": "PT15M",
        "minObservations": 5,
        "sourceText": "Predose, 15, 30, \n60, 120, 240 min"
      },
      {
        "id": "rep_interval_9",
        "type": "Interval",
        "interval": "PT5M",
        "minObservations": 12,
        "sourceText": "Predose, 5, 10, 15, \n20, 25, 30, 40, 50, \n60, 90, 120, 240 \nmin"
      },
      {
        "id": "rep_interval_13",
        "type": "Interval",
        "interval": "PT15M",
        "minObservations": 4,
        "sourceText": "Predose, 15, 30, \n60, 120 min"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "P28D",
        "endOffset": "P2D",
        "sourceText": "Days -28\nto -2"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "sourceText": "washout period"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "sourceText": "Screening\nPeriod"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "washout \nperiod"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_window_19",
        "type": "Continuous",
        "sourceText": "2 days \nafter"
      },
      {
        "id": "rep_window_23",
        "type": "Continuous",
        "sourceText": "6 hours after"
      },
      {
        "id": "rep_window_24",
        "type": "Continuous",
        "sourceText": "4 hours after"
      }
    ],
    "samplingConstraints": [
      {
        "id": "pk_sampling_1",
        "activityId": "PK_Blood_Sampling",
        "minPerWindow": 4,
        "windowDuration": "PT3H",
        "timepoints": [
          "15 minutes",
          "30 minutes",
          "60 minutes",
          "120 minutes"
        ],
        "sourceText": "Predose, 15, 30, \n60, 120 min"
      }
    ],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "WASHOUT",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "crossover study"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "BASELINE",
          "TREATMENT",
          "WASHOUT",
          "FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Treatment Admission Visit",
          "Day 1",
          "End of Study",
          "Screening Visit",
          "Screening"
        ],
        "sourceText": "[{'condition': 'Insufficient response to glucagon administration', 'path': ['RESCUE_PROCEDURES']}, {'condition': 'Subject meets criteria for discontinuation from the study', 'path': ['EARLY_TERMINATION', 'FOLLOW_UP']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 8; SINGLE signals: 4"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Window",
        "rationale": "WINDOW signals: 3; EPISODE signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Episode",
        "rationale": "WINDOW signals: 1; EPISODE signals: 2; SINGLE signals: 2; RECURRING signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 5; SINGLE signals: 2"
      },
      {
        "activityId": "Concomitant\nMedications",
        "executionType": "Single",
        "rationale": "WINDOW signals: 2; EPISODE signals: 1; SINGLE signals: 4"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Window",
        "rationale": "WINDOW signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Glucose Measurement",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Insulin Infusion",
        "executionType": "Single",
        "rationale": "WINDOW signals: 3; SINGLE signals: 6"
      },
      {
        "activityId": "Dosing",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 10; SINGLE signals: 1"
      },
      {
        "activityId": "Epro",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutDuration": "3 to 14 days",
      "washoutRequired": true,
      "carryoverPrevention": "Patients will be administered a single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14 days.",
      "sourceText": "crossover study"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "frequency_daily",
        "text": "multiple daily injection of long-acting insulin analog",
        "footnoteId": "[A]",
        "structuredCondition": "treatment.regimen(insulin.long_acting, frequency.multiple_daily_injection)",
        "appliesToActivityIds": [
          "Subject Eligibility"
        ],
        "sourceText": "multiple daily injection of long-acting insulin analog"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "women of childbearing potential participating must test negative for \npregnancy prior to initiation of treatment as indicated by a negative serum \npregnancy test at the screening visit followed by a negative urine \npregnancy test within",
        "footnoteId": "[A]",
        "structuredCondition": "eligibility.requires(population.WOCBP, sequence(test.pregnancy.serum.negative@screening, test.pregnancy.urine.negative.before(treatment.initiation)))",
        "appliesToActivityIds": [
          "Pregnancy Test (Serum)",
          "Pregnancy Test (Urine)"
        ],
        "sourceText": "women of childbearing potential participating must test negative for \npregnancy prior to initiation "
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "either one highly effective method of contraception or a combination \nof",
        "footnoteId": "[B]",
        "structuredCondition": "eligibility.requires(contraception.highly_effective OR contraception.combination)",
        "appliesToActivityIds": [
          "Subject Eligibility"
        ],
        "sourceText": "either one highly effective method of contraception or a combination \nof"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "postmenopausal, defined as either:",
        "footnoteId": "[B]",
        "structuredCondition": "eligibility.definition.start(status.postmenopausal)",
        "appliesToActivityIds": [
          "Subject Eligibility"
        ],
        "sourceText": "postmenopausal, defined as either:"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "cessation of menses for at least",
        "footnoteId": "[a]",
        "structuredCondition": "eligibility.definition.part(status.postmenopausal, condition.menses_cessation, duration.gte(unknown))",
        "appliesToActivityIds": [
          "Subject Eligibility"
        ],
        "sourceText": "cessation of menses for at least"
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "if warranted and agreed upon between both the investigator and sponsor",
        "footnoteId": "(s)",
        "structuredCondition": "condition.if(warranted AND agreement(investigator, sponsor))",
        "sourceText": "if warranted and agreed upon between both the investigator and sponsor"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "Predose time point will be\nbetween insulin infusion \nstop and study treatment",
        "footnoteId": "L.",
        "structuredCondition": "timing.between(event.insulin_infusion_stop, event.study_treatment_administration)",
        "appliesToActivityIds": [
          "Predose Assessments"
        ],
        "sourceText": "Predose time point will be\nbetween insulin infusion \nstop and study treatment"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "a\nSamples for immunogenicity, should be collected every",
        "footnoteId": "s.",
        "structuredCondition": "frequency.every(unknown)",
        "appliesToActivityIds": [
          "Immunogenicity Sample Collection"
        ],
        "sourceText": "a\nSamples for immunogenicity, should be collected every"
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_after",
        "text": "Note:  if multiple procedures take place at the same time point, the following order of the procedure should be used:  ECG, vital signs, and venipuncture",
        "footnoteId": "r.",
        "structuredCondition": "sequence.order(ECG, vital_signs, venipuncture)",
        "appliesToActivityIds": [
          "ECG",
          "Vital Signs",
          "Venipuncture"
        ],
        "sourceText": "Note:  if multiple procedures take place at the same time point, the following order of the procedur"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "The nature of any conditions present at the time of the physical examination and any preexisting \nconditions will be documented",
        "footnoteId": "G.",
        "structuredCondition": "documentation.required(physical_examination.conditions.present AND conditions.preexisting)",
        "appliesToActivityIds": [
          "Physical Examination"
        ],
        "sourceText": "The nature of any conditions present at the time of the physical examination and any preexisting \nco"
      },
      {
        "id": "fn_cond_11",
        "conditionType": "general",
        "text": "Patients who are not enrolled within",
        "footnoteId": "t.",
        "sourceText": "Patients who are not enrolled within"
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as \nprotocol waivers or exemptions, are not permitted",
        "footnoteId": "y.",
        "sourceText": "Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as \np"
      },
      {
        "id": "fn_cond_13",
        "conditionType": "general",
        "text": "The patient may \nchoose to use a double barrier method of contraception",
        "footnoteId": "d.",
        "sourceText": "The patient may \nchoose to use a double barrier method of contraception"
      },
      {
        "id": "fn_cond_14",
        "conditionType": "general",
        "text": "Thus, each barrier method must include use of a \nspermicide",
        "footnoteId": "d.",
        "sourceText": "Thus, each barrier method must include use of a \nspermicide"
      },
      {
        "id": "fn_cond_15",
        "conditionType": "general",
        "text": "Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \nwill be destroyed within",
        "footnoteId": "y.",
        "sourceText": "Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \n"
      },
      {
        "id": "fn_cond_16",
        "conditionType": "procedure_conditional",
        "text": "Certain samples may be \nretained for a longer period, if necessary, to comply with applicable laws, regulations, or \nlaboratory certification standards",
        "footnoteId": "s.",
        "sourceText": "Certain samples may be \nretained for a longer period, if necessary, to comply with applicable laws, "
      },
      {
        "id": "fn_cond_17",
        "conditionType": "timing_after",
        "text": "Blood pressure and pulse rate should be measured after at least",
        "footnoteId": "d.",
        "sourceText": "Blood pressure and pulse rate should be measured after at least"
      },
      {
        "id": "fn_cond_18",
        "conditionType": "general",
        "text": "Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or \nposture-induced symptoms",
        "footnoteId": "e.",
        "sourceText": "Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or \n"
      },
      {
        "id": "fn_cond_19",
        "conditionType": "general",
        "text": "If the patient feels unable to stand, supine \nvital signs only will be recorded",
        "footnoteId": "s.",
        "sourceText": "If the patient feels unable to stand, supine \nvital signs only will be recorded"
      },
      {
        "id": "fn_cond_20",
        "conditionType": "general",
        "text": "Single ECGs will be collected and stored locally at the investigator’s site",
        "footnoteId": "F.",
        "sourceText": "Single ECGs will be collected and stored locally at the investigator’s site"
      },
      {
        "id": "fn_cond_21",
        "conditionType": "general",
        "text": "The central ECG laboratory will perform a basic quality control check",
        "footnoteId": "y.",
        "sourceText": "The central ECG laboratory will perform a basic quality control check"
      },
      {
        "id": "fn_cond_22",
        "conditionType": "general",
        "text": "At a future time, the stored \nECG data may be overread at the central ECG laboratory for further evaluation of machine-read \nmeasurements or to meet regulatory requirements",
        "footnoteId": "e.",
        "sourceText": "At a future time, the stored \nECG data may be overread at the central ECG laboratory for further eva"
      },
      {
        "id": "fn_cond_23",
        "conditionType": "general",
        "text": "Concentrations of glucagon will be assayed using a validated liquid chromatography with \ntandem mass spectrometry method",
        "footnoteId": "r.",
        "sourceText": "Concentrations of glucagon will be assayed using a validated liquid chromatography with \ntandem mass"
      },
      {
        "id": "fn_cond_24",
        "conditionType": "general",
        "text": "The samples will be stored for up to a maximum of",
        "footnoteId": "s.",
        "sourceText": "The samples will be stored for up to a maximum of"
      },
      {
        "id": "fn_cond_25",
        "conditionType": "general",
        "text": "To interpret the results of \nimmunogenicity, a venous blood sample may be collected at the same time points to determine \nthe concentrations of glucagon",
        "footnoteId": "n.",
        "sourceText": "To interpret the results of \nimmunogenicity, a venous blood sample may be collected at the same time"
      },
      {
        "id": "fn_cond_26",
        "conditionType": "general",
        "text": "A PK sample may be collected at these \nsame time points",
        "footnoteId": "t.",
        "sourceText": "A PK sample may be collected at these \nsame time points"
      },
      {
        "id": "fn_cond_27",
        "conditionType": "general",
        "text": "Treatment-emergent antidrug antibodies",
        "footnoteId": "r.",
        "sourceText": "Treatment-emergent antidrug antibodies"
      },
      {
        "id": "fn_cond_28",
        "conditionType": "general",
        "text": "A PK \nsample may be collected at the follow-up immunogenicity assessment",
        "footnoteId": "t.",
        "sourceText": "A PK \nsample may be collected at the follow-up immunogenicity assessment"
      },
      {
        "id": "fn_cond_29",
        "conditionType": "general",
        "text": "Every attempt should be made to contact \npatients for the follow-up immunogenicity assessment; however, if patients are unwilling or \nunable to return for the visit, this is not considered a protocol violation",
        "footnoteId": "r.",
        "sourceText": "Every attempt should be made to contact \npatients for the follow-up immunogenicity assessment; howev"
      },
      {
        "id": "fn_cond_30",
        "conditionType": "general",
        "text": "male patients: agree to use an effective method of contraception for the \nduration of the study and for",
        "footnoteId": "[2]",
        "sourceText": "male patients: agree to use an effective method of contraception for the \nduration of the study and "
      },
      {
        "id": "fn_cond_31",
        "conditionType": "general",
        "text": "female patients:",
        "footnoteId": "[3]",
        "sourceText": "female patients:"
      },
      {
        "id": "fn_cond_32",
        "conditionType": "general",
        "text": "Study Population\nEligibility of patients for the study will be based on the results of screening medical history, \nphysical examination, vital signs, clinical laboratory tests, and ECG",
        "footnoteId": "6.",
        "sourceText": "Study Population\nEligibility of patients for the study will be based on the results of screening med"
      },
      {
        "id": "fn_cond_33",
        "conditionType": "timing_after",
        "text": "Inclusion Criteria\nPatients are eligible for inclusion in the study only if they meet all of the following criteria at \nscreening and/or enrollment:",
        "footnoteId": "1.",
        "sourceText": "Inclusion Criteria\nPatients are eligible for inclusion in the study only if they meet all of the fol"
      },
      {
        "id": "fn_cond_34",
        "conditionType": "general",
        "text": "Study Assessments and Procedures\nSection",
        "footnoteId": "9.",
        "sourceText": "Study Assessments and Procedures\nSection"
      },
      {
        "id": "fn_cond_35",
        "conditionType": "general",
        "text": "Efficacy Assessments\nPlasma glucose levels will be measured as described in Section",
        "footnoteId": "1.",
        "sourceText": "Efficacy Assessments\nPlasma glucose levels will be measured as described in Section"
      },
      {
        "id": "fn_cond_36",
        "conditionType": "general",
        "text": "Primary Efficacy Assessments\nThe primary efficacy measure is the proportion of patients achieving treatment success, defined \nas either an increase in PG to >",
        "footnoteId": "1.",
        "sourceText": "Primary Efficacy Assessments\nThe primary efficacy measure is the proportion of patients achieving tr"
      },
      {
        "id": "fn_cond_37",
        "conditionType": "general",
        "text": "Secondary Efficacy Assessments\nSecondary efficacy measures will be determined from the pharmacodynamic",
        "footnoteId": "2.",
        "sourceText": "Secondary Efficacy Assessments\nSecondary efficacy measures will be determined from the pharmacodynam"
      },
      {
        "id": "fn_cond_38",
        "conditionType": "general",
        "text": "Exploratory Efficacy Assessments\nSubjective hypoglycemia symptoms will be assessed using a self-reported assessment tool",
        "footnoteId": "3.",
        "sourceText": "Exploratory Efficacy Assessments\nSubjective hypoglycemia symptoms will be assessed using a self-repo"
      },
      {
        "id": "fn_cond_39",
        "conditionType": "general",
        "text": "Insulin-induced Hypoglycemia\nA study investigator, or qualified designee, must be present at the bedside for clinical \nassessments of the patient during the insulin infusion and for the",
        "footnoteId": "1.",
        "sourceText": "Insulin-induced Hypoglycemia\nA study investigator, or qualified designee, must be present at the bed"
      },
      {
        "id": "fn_cond_40",
        "conditionType": "general",
        "text": "Treatment of Overdose\nFor the purposes of this study, an overdose of LY",
        "footnoteId": "4.",
        "sourceText": "Treatment of Overdose\nFor the purposes of this study, an overdose of LY"
      },
      {
        "id": "fn_cond_41",
        "conditionType": "general",
        "text": "Laboratory Tests\nFor each patient, laboratory tests detailed in Appendix",
        "footnoteId": "1.",
        "sourceText": "Laboratory Tests\nFor each patient, laboratory tests detailed in Appendix"
      },
      {
        "id": "fn_cond_42",
        "conditionType": "general",
        "text": "Vital Signs\nFor each patient, vital sign measurements should be conducted according to the Schedule of \nActivities",
        "footnoteId": "2.",
        "sourceText": "Vital Signs\nFor each patient, vital sign measurements should be conducted according to the Schedule "
      },
      {
        "id": "fn_cond_43",
        "conditionType": "general",
        "text": "Electrocardiograms\nFor each patient, single and triplicate ECGs should be collected according to the Schedule of \nActivities",
        "footnoteId": "3.",
        "sourceText": "Electrocardiograms\nFor each patient, single and triplicate ECGs should be collected according to the"
      },
      {
        "id": "fn_cond_44",
        "conditionType": "general",
        "text": "Bioanalysis\nSamples will be analyzed at a laboratory approved by the sponsor and stored at a facility \ndesignated by the sponsor",
        "footnoteId": "1.",
        "sourceText": "Bioanalysis\nSamples will be analyzed at a laboratory approved by the sponsor and stored at a facilit"
      },
      {
        "id": "fn_cond_45",
        "conditionType": "general",
        "text": "Pharmacodynamics\nAt times specified in the Schedule of Activities",
        "footnoteId": "7.",
        "sourceText": "Pharmacodynamics\nAt times specified in the Schedule of Activities"
      },
      {
        "id": "fn_cond_46",
        "conditionType": "general",
        "text": "Immunogenicity Assessments\nAt the visits and times specified in the Schedule of Activities",
        "footnoteId": "1.",
        "sourceText": "Immunogenicity Assessments\nAt the visits and times specified in the Schedule of Activities"
      },
      {
        "id": "fn_cond_47",
        "conditionType": "general",
        "text": "If the \nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \ndefinition of treatment emergent, then, at the discretion of the sponsor, patients should be called \nback to the site for follow-up immunogenicity assessment",
        "footnoteId": "6.",
        "sourceText": "If the \nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \nde"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Exploratory Endpoint 1",
        "endpointType": "Exploratory",
        "inputs": [
          "insulin",
          "PR",
          "CR",
          "PG",
          "glucose",
          "efficacy outcomes",
          "is the",
          "OS"
        ],
        "timeWindow": {
          "reference": "nadir within",
          "duration": "P60D"
        },
        "algorithm": "either an increase in pg to >70 mg/dl or an increase of >20 mg/dl from nadir within \n30 minutes after administration of glucagon",
        "successCriteria": "treatment success, defined \nas either an increase in pg to >70 mg/dl or an increase of >20 mg/dl from nadir within \n30 minutes after administration of glucagon",
        "unit": "mg/dl",
        "sourceText": "--- Page 36 ---\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 35\nLY900018\n9. Study Assessments and Procedures\nSection 2 lists the Schedule of Activities, detailing the study procedures and their "
      },
      {
        "id": "ep_2",
        "name": "is to demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the \nproportion (NIM=10%) of Ja",
        "endpointType": "Primary",
        "inputs": [
          "PR",
          "treatment success",
          "CR",
          "PG",
          "to raise",
          "glucose",
          "OS"
        ],
        "timeWindow": {
          "reference": "pg nadir",
          "duration": "PT30M"
        },
        "algorithm": "either an increase in pg to ≥70 mg/dl or an increase of ≥20 mg/dl from pg nadir \nwithin 30 minutes after receiving study treatment",
        "successCriteria": "either an increase in pg to ≥70 mg/dl or an increase of ≥20 mg/dl from pg nadir \nwithin 30 minutes after receiving study treatment",
        "unit": "mg",
        "sourceText": "primary objective is to demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the \nproportion (NIM=10%) of Japanese patients with T1DM or T2DM who achieve treatment \nsuccess without receiving"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "PG concentrations",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "wilcoxon signed",
          "baseline",
          "observed medians",
          "glucose",
          "hemoglobin",
          "descriptive methodology",
          "consultation with",
          "AST",
          "creatinine",
          "actual time",
          "nca",
          "concentrations of",
          "preferred terms",
          "clarke hypoglycemia",
          "standard \ndescriptive",
          "standard noncompartmental",
          "ALT",
          "a self",
          "HbA1c"
        ],
        "derivationRule": "the sum of the scores for each question",
        "baselineVisit": "day\n-1",
        "analysisWindow": "day 1",
        "unit": "described",
        "sourceText": "--- Page 19 ---\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 18\nLY900018\nScreening\nPeriod 1\nWash \nout\nPeriod 2\nFollow-up/ED\nAdditional \nFollow-up for \nTE ADAa\nComments\nProcedure\nDays -28\nto -2\nD"
      },
      {
        "id": "dv_2",
        "name": "concentrations of",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "glucose",
          "change from"
        ],
        "derivationRule": "post_value - baseline_value",
        "sourceText": "\n1.5 hours\n\n\n--- Page 51 ---\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 50\nLY900018\nBGmax\nmaximal plasma glucose concentration\nDurationabove\nduration above normal range\nDurationbelow\nduration "
      },
      {
        "id": "dv_3",
        "name": "may be",
        "variableType": "Custom",
        "sourceVariables": [
          "glucose",
          "wilcoxon signed",
          "AST",
          "HbA1c"
        ],
        "derivationRule": "210 minutes per period/3 = 70 samples per period × 2 periods = 140 samples total",
        "baselineVisit": "screening",
        "unit": "90",
        "sourceText": "\n1.5 hours\nBGmax\nmaximal plasma glucose concentration\nTmax\ntime to maximal concentration\nBaseline PG concentrations will be concentrations from samples obtained immediately prior to \nglucagon dosing ("
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Completed",
        "Discontinued",
        "Withdrawn",
        "Death",
        "LostToFollowUp"
      ],
      "states": [
        "Screening",
        "Enrolled",
        "OnTreatment",
        "FollowUp",
        "Completed",
        "Discontinued",
        "Withdrawn",
        "Death"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Enrolled",
          "trigger": "Progress from Screening to Enrolled"
        },
        {
          "fromState": "Enrolled",
          "toState": "OnTreatment",
          "trigger": "Progress from Enrolled to OnTreatment"
        },
        {
          "fromState": "OnTreatment",
          "toState": "FollowUp",
          "trigger": "Progress from OnTreatment to FollowUp"
        },
        {
          "fromState": "FollowUp",
          "toState": "Completed",
          "trigger": "Progress from FollowUp to Completed"
        },
        {
          "fromState": "OnTreatment",
          "toState": "Discontinued",
          "trigger": "Discontinuation from treatment"
        },
        {
          "fromState": "OnTreatment",
          "toState": "OnTreatment",
          "trigger": "Enter washout period",
          "guardCondition": "period_complete AND NOT last_period"
        }
      ]
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "that delivers",
        "frequency": "QD",
        "route": "Intranasal",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": "Diabetes Mellitus\nRationale:\nNasal glucagon (LY900018) is a powder formulation of human glucagon for the rescue treatment of hypoglycemia \npackaged in a user-friendly, single-use, nasal dosing device "
      },
      {
        "id": "dosing_2",
        "treatmentName": "demonstrate that",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "ments to increase PG.  The nadir is defined as the minimum PG measurement at the time of \nor within 10 minutes following glucagon administration.\nObjectives/Endpoints:\nObjectives\nEndpoints\nPrimary\nTo "
      },
      {
        "id": "dosing_3",
        "treatmentName": "non-inferior to",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": "s defined as the minimum PG measurement at the time of \nor within 10 minutes following glucagon administration.\nObjectives/Endpoints:\nObjectives\nEndpoints\nPrimary\nTo demonstrate that 3 mg LY900018 is "
      },
      {
        "id": "dosing_4",
        "treatmentName": "tolerability of",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "minutes \nafter administration of glucagon.  The nadir is defined \nas the minimum PG value at the time of or within \n10 minutes following glucagon administration.\nSecondary\n\nTo compare the safety and "
      },
      {
        "id": "dosing_5",
        "treatmentName": "LY900018 with",
        "frequency": "QD",
        "route": "Intranasal",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": "tration of glucagon.  The nadir is defined \nas the minimum PG value at the time of or within \n10 minutes following glucagon administration.\nSecondary\n\nTo compare the safety and tolerability of 3 mg \n"
      },
      {
        "id": "dosing_6",
        "treatmentName": "profile of",
        "frequency": "QD",
        "route": "Intranasal",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "he minimum PG value at the time of or within \n10 minutes following glucagon administration.\nSecondary\n\nTo compare the safety and tolerability of 3 mg \nLY900018 with 1 mg IMG\n\nTo characterize the PK "
      },
      {
        "id": "dosing_7",
        "treatmentName": "compared to",
        "frequency": "QD",
        "route": "Intranasal",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": " time of or within \n10 minutes following glucagon administration.\nSecondary\n\nTo compare the safety and tolerability of 3 mg \nLY900018 with 1 mg IMG\n\nTo characterize the PK profile of 3 mg LY900018 \n"
      },
      {
        "id": "dosing_8",
        "treatmentName": "to",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 250.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "14 days",
        "sourceText": "\n14 days\nDay\n-1\nDay 1\nWithin \n28±2 days \nafter last \nstudy \ntreatment\nClinical Assessments\nInformed Consent\nX\nRandomization\nX\nAdmission to CRU\nX\nX\nAdmission can be \nrescheduled if PG level is \nnot 90 "
      },
      {
        "id": "dosing_9",
        "treatmentName": "which delivers",
        "frequency": "QD",
        "route": "Intranasal",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": "iabetes treatments. LY900018 is a \npowder formulation of synthetic human glucagon in a user-friendly, single-use, nasal dosing \n\n\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 20\nLY900018\ndevice "
      },
      {
        "id": "dosing_10",
        "treatmentName": "efficacy between",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "leted in non-Japanese adults with T1DM \nand T2DM:  Study IGBC, Study I8R-MC-IGBA (IGBA), and an actual use study\n(Study I8R-MC-B002 [B002]).  Studies IGBC and IGBA demonstrated comparable safety and \n"
      },
      {
        "id": "dosing_11",
        "treatmentName": "LY900018 and",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": "adults with T1DM \nand T2DM:  Study IGBC, Study I8R-MC-IGBA (IGBA), and an actual use study\n(Study I8R-MC-B002 [B002]).  Studies IGBC and IGBA demonstrated comparable safety and \nefficacy between 3 mg "
      },
      {
        "id": "dosing_12",
        "treatmentName": "effectiveness of",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": "ctable glucagon in reversing insulin-induced \nhypoglycemia in adult patients with T1DM only (Study IGBA) or patients with T2DM and \nT1DM (IGBC).  Study B002 was an actual use study that evaluated the "
      },
      {
        "id": "dosing_13",
        "treatmentName": "glucose around",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 50.0,
            "unit": "mg"
          }
        ],
        "sourceText": "this study.\nThis study will expose patients to an insulin-induced hypoglycemia meant to simulate \nhypoglycemia in a controlled setting.  The procedure of insulin-induced hypoglycemia targeting \nnadir "
      },
      {
        "id": "dosing_14",
        "treatmentName": "administered either",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 60.0,
            "unit": "mg"
          }
        ],
        "sourceText": "erial blood sampling will be conducted to monitor bedside PG for safety.  \nThe insulin infusion will be stopped once the PG level reaches <60 mg/dL and approximately \n5 minutes later patients will be "
      },
      {
        "id": "dosing_15",
        "treatmentName": "LY900018 or",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 60.0,
            "unit": "mg"
          }
        ],
        "sourceText": " be conducted to monitor bedside PG for safety.  \nThe insulin infusion will be stopped once the PG level reaches <60 mg/dL and approximately \n5 minutes later patients will be administered either 3 mg "
      },
      {
        "id": "dosing_16",
        "treatmentName": "assessment of",
        "frequency": "QD",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "f the last visit or last scheduled procedure shown in the Schedule of \nActivities (Section 2) for the last patient.\n5.4.\nScientific Rationale for Study Design\nThis study design involves an open-label "
      },
      {
        "id": "dosing_17",
        "treatmentName": "of approximately",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 50.0,
            "unit": "mg"
          },
          {
            "amount": 20.0,
            "unit": "mg"
          },
          {
            "amount": 60.0,
            "unit": "mg"
          }
        ],
        "sourceText": "n increase of ≥20 mg/dL from the PG nadir within 30 minutes \nafter receiving glucagon, without the patient receiving additional actions to increase glucose.  It \nis believed that an expected PG nadir "
      },
      {
        "id": "dosing_18",
        "treatmentName": "infusion at",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 60.0,
            "unit": "mg"
          },
          {
            "amount": 50.0,
            "unit": "mg"
          }
        ],
        "sourceText": "ng glucagon, without the patient receiving additional actions to increase glucose.  It \nis believed that an expected PG nadir of approximately 50 mg/dL (approximately 5 minutes after \nstop of insulin "
      },
      {
        "id": "dosing_19",
        "treatmentName": "compare \nagainst",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": " hypoglycemia\nin Japan.\nBased on LY900018 exposure, efficacy, and safety, the 3-mg dose was selected for the Phase 3 \nstudies.  Therefore, in the current study, the 3-mg LY900018 dose will be used to "
      },
      {
        "id": "dosing_20",
        "treatmentName": "have donated",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 400.0,
            "unit": "ml"
          }
        ],
        "durationDescription": "12 weeks",
        "sourceText": "igen\n[30] show evidence of syphilis and/or are positive for syphilis test\n[31] are women who are lactating\n[32] use of daily systemic beta-blocker, indomethacin, warfarin, anticholinergic \ndrugs\n[33] "
      },
      {
        "id": "dosing_21",
        "treatmentName": "months is",
        "frequency": "QW",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1200.0,
            "unit": "ml"
          },
          {
            "amount": 400.0,
            "unit": "ml"
          },
          {
            "amount": 800.0,
            "unit": "ml"
          }
        ],
        "durationDescription": "12 weeks",
        "sourceText": "400 mL or more blood in the last 12 weeks (males) or in the last \n16 weeks (females), or any blood donation (including apheresis) within the \nlast 4 weeks, or total volume of blood donation within 12 "
      },
      {
        "id": "dosing_22",
        "treatmentName": "that exceeds",
        "frequency": "QW",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 21.0,
            "unit": "units"
          },
          {
            "amount": 14.0,
            "unit": "units"
          }
        ],
        "durationDescription": "12 months",
        "sourceText": "f blood donation within 12 months is 1200 mL \n(males)/800 mL (females) or more at screening\n\n\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 29\nLY900018\n[34] have an average weekly alcohol intake "
      },
      {
        "id": "dosing_23",
        "treatmentName": "oz or",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 360.0,
            "unit": "ml"
          },
          {
            "amount": 45.0,
            "unit": "ml"
          },
          {
            "amount": 150.0,
            "unit": "ml"
          }
        ],
        "sourceText": "21 units per week (males \nup to age 65) and 14 units per week (males over 65 and females), or are \nunwilling to stop alcohol consumption from Day -2 to discharge from CRU in \neach period (1 unit = 12 "
      },
      {
        "id": "dosing_24",
        "treatmentName": "oz \nor",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 45.0,
            "unit": "ml"
          },
          {
            "amount": 360.0,
            "unit": "ml"
          },
          {
            "amount": 150.0,
            "unit": "ml"
          }
        ],
        "sourceText": "ts per week (males over 65 and females), or are \nunwilling to stop alcohol consumption from Day -2 to discharge from CRU in \neach period (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 "
      },
      {
        "id": "dosing_25",
        "treatmentName": "not exceed",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 21.0,
            "unit": "units"
          },
          {
            "amount": 14.0,
            "unit": "units"
          }
        ],
        "sourceText": "Tobacco\nPatients should refrain from caffeine-containing food/beverages (eg, cola, chocolate drinks, tea,\nand coffee) from Day -1 to discharge from CRU in each period.  Patient alcohol intake should \n"
      },
      {
        "id": "dosing_26",
        "treatmentName": "comparison of",
        "frequency": "QD",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "r participation in this study (screen failure) may not be \nre-screened.\n\n\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 31\nLY900018\n7. Treatment\n7.1.\nTreatment Administered\nThis study involves a "
      },
      {
        "id": "dosing_27",
        "treatmentName": "nasally to",
        "frequency": "QD",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": "y not be \nre-screened.\n\n\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 31\nLY900018\n7. Treatment\n7.1.\nTreatment Administered\nThis study involves a comparison of 3 mg of LY900018 administered once "
      },
      {
        "id": "dosing_28",
        "treatmentName": "Dosage Levels",
        "frequency": "QD",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "g \nglucagon administered IM (comparator).  Table IGBJ.2 shows the study treatment information.\nTable IGBJ.2.\nStudy Treatments\nTreatment Name\nLY900018\nGlucaGen\nDosage Formulation\nDry powder\nDry powder\n"
      },
      {
        "id": "dosing_29",
        "treatmentName": "glucagon",
        "frequency": "QD",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": "tered IM (comparator).  Table IGBJ.2 shows the study treatment information.\nTable IGBJ.2.\nStudy Treatments\nTreatment Name\nLY900018\nGlucaGen\nDosage Formulation\nDry powder\nDry powder\nDosage Levels\n3 mg "
      },
      {
        "id": "dosing_30",
        "treatmentName": "into",
        "frequency": "QD",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 50.0,
            "unit": "ml"
          }
        ],
        "sourceText": "ection upon hypoglycemia onset\nThe procedure for insulin-induced hypoglycemia will require an IV infusion of diluted human \nregular insulin (0.3 U/mL by diluting 15 U human regular insulin [100 U/mL] "
      },
      {
        "id": "dosing_31",
        "treatmentName": "maximum",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 2.0,
            "unit": "g"
          },
          {
            "amount": 1.0,
            "unit": "g"
          }
        ],
        "sourceText": "), opiate medications (eg, morphine),\nand medications with anti-emetic effects (eg, promethazine, prochlorperazine).\nIn general, concomitant medication should be avoided; however, acetaminophen (1 g, "
      },
      {
        "id": "dosing_32",
        "treatmentName": "either",
        "frequency": "QD",
        "route": "Intranasal",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "atory) and/or \nglucagon (PK) measurements according to the Schedule of Activities (Section 2).\n9.2.2. Glucagon Administration\nApproximately 5 minutes after the insulin infusion has stopped, glucagon ("
      },
      {
        "id": "dosing_33",
        "treatmentName": "Administration\nGlucaGen",
        "frequency": "QD",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": ".  If a patient sneezes immediately after administration, document using \nthe Nasal and Non-nasal Score Questionnaire (see Appendix 6 for a copy of the questionnaire).\n9.2.2.2.\nIntramuscular Glucagon "
      },
      {
        "id": "dosing_34",
        "treatmentName": "The lyophilized",
        "frequency": "QD",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "the Nasal and Non-nasal Score Questionnaire (see Appendix 6 for a copy of the questionnaire).\n9.2.2.2.\nIntramuscular Glucagon Administration\nGlucaGen 1 mg for injection will be used as a comparator.  "
      },
      {
        "id": "dosing_35",
        "treatmentName": "reconstituted with",
        "frequency": "QD",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.1,
            "unit": "ml"
          }
        ],
        "sourceText": "aire (see Appendix 6 for a copy of the questionnaire).\n9.2.2.2.\nIntramuscular Glucagon Administration\nGlucaGen 1 mg for injection will be used as a comparator.  The lyophilized 1 mg glucagon will \nbe "
      },
      {
        "id": "dosing_36",
        "treatmentName": "dose of",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "ramuscular Glucagon Administration\nGlucaGen 1 mg for injection will be used as a comparator.  The lyophilized 1 mg glucagon will \nbe reconstituted with 1.1 mL diluent according to the instruction.  A "
      },
      {
        "id": "dosing_37",
        "treatmentName": "concentration of",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "e lyophilized 1 mg glucagon will \nbe reconstituted with 1.1 mL diluent according to the instruction.  A dose of 1 mg of glucagon in \n\n\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 37\nLY900018\na "
      }
    ],
    "visitWindows": [
      {
        "id": "visit_1",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 28,
        "windowAfter": 28,
        "isRequired": true,
        "visitNumber": 1,
        "sourceText": "Patients will undergo a screening examination within 28 days prior to enrollment.  Patients will be administered a \nsingle dose in Periods 1 and 2, which will be separated by a washout period of 3 to "
      },
      {
        "id": "visit_7",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "Samples for immunogenicity, should be collected every 12 weeks (84±7 days) until the titer returns to baseline (ie, returns to within a single 2-fold dilution of \nthe baseline titer) or until 1 year a"
      },
      {
        "id": "visit_2",
        "visitName": "Early Termination",
        "targetDay": 1,
        "windowBefore": 3,
        "windowAfter": 14,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14 days.  Patients will return for \na follow-up visit 26 to 30 days after the last study treatment.\nNumber of Patien"
      },
      {
        "id": "visit_3",
        "visitName": "Visit 26",
        "targetDay": 1,
        "windowBefore": 26,
        "windowAfter": 30,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "a follow-up visit 26 to 30 days after the last study treatment.\nNumber of Patients:\nSeventy five patients may be enrolled in order to have at least 66 patients (at least 30 patients with T1DM and "
      },
      {
        "id": "visit_5",
        "visitName": "Day 1",
        "targetDay": 1,
        "windowBefore": 3,
        "windowAfter": 14,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "Day 1\n3 to\n14 days"
      },
      {
        "id": "visit_6",
        "visitName": "Randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "Randomization\nX\nAdmission to CRU"
      },
      {
        "id": "visit_8",
        "visitName": "Visit 1",
        "targetDay": 1,
        "windowBefore": 1,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "dosing visit 1 to 7 days later.\nFor safety monitoring during the hypoglycemia induction procedure, bedside PG levels will be \nmeasured using the glucose analyzer no more than 10 minutes apart while PG"
      },
      {
        "id": "visit_9",
        "visitName": "Eos",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 8,
        "sourceText": "Eosinophils\nAspartate aminotransferase (AST)\nBasophils"
      },
      {
        "id": "visit_4",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 26,
        "windowAfter": 30,
        "isRequired": true,
        "visitNumber": 9,
        "sourceText": "a follow-up visit 26 to 30 days after the last study treatment.\nNumber of Patients:\nSeventy five patients may be enrolled in order to have at least 66 patients (at least 30 patients with T1DM and "
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "dynamic randomization",
      "centralRandomization": true,
      "sourceText": "I8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 23\nLY900018\n5. Study Design\n5.1.\nOverall Design\nThis is a Phase 3, multicenter, randomized, open-label, active comparator, single-dose, 2-period, \n2-"
    }
  }
}